Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)

RCT (n=106) found that addition of vemurafenib improved progression free survival (HR 0.50, p=0.001), response rate (17% vs 4% p=0.05) and disease control rate (65% vs 21%, p<0.001). There was also a significant decline in DNA BRAFV600E variant allele (87% vs 0%, p<0.001).

Journal of Clinical Oncology